From no evidence of disease activity in MS to studies of a new treatment for periodic paralysis, AAN 2016 featured many exciting clinical trials.
Some of the best new research developments were highlighted at the Clinical Trials plenary session on April 20 during AAN 2016. In part 1 of this slideshow, we share results of the first four of eight trials featured. Natalia S. Rost, MD, Vice Chair of the Science Committee and Petra Kauffman, MS, member of the Science Committee, led the session.
Clinical Trial Highlights: AAN 2016 â Part 1
Efficacy and Safety of Dichlorphenamide for the Treatment of Periodic Paralysis: a Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial
Dichlorphenamide for Periodic Paralysis â intro
Dichlorphenamide for Periodic Paralysis â results & conclusions
Interim Results from a Phase 2/3 Study of the Efficacy and Safety of Ex Vivo Gene Therapy with Lentiviral Vector (Lenti D) for Childhood Cerebral Adrenoleukodystrophy
Lenti D for Childhood Cerebral Adrenoleukodystrophy â intro
Lenti D for Childhood Cerebral Adrenoleukodystrophy â results & conclusions
KINECT 3: a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Valbenazine (NBI-98854) for Tardive Dyskinesia
Valbenazine for Tardive Dyskinesia â intro
Valbenazine for Tardive Dyskinesia â results & conclusions
Ocrelizumab No Evidence of Disease Activity (NEDA) Status at 96 Weeks in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III Double-Blind, Double-Dummy, Interferon beta-1a-Controlled OPERA I and OPERA II Studies
